Merck completes $10B acquisition of Verona Pharma, adding first-in-class COPD therapy Ohtuvayre

Rahway, NJ, October 7, 2025 (Business Wire) -- Merck finalized its $10 billion acquisition of Verona Pharma, making it a wholly owned subsidiary and delisting its shares from Nasdaq. The deal brings Ohtuvayre® (ensifentrine), a first-in-class dual PDE3 and PDE4 inhibitor approved in 2024 for COPD maintenance, into Merck’s cardio-pulmonary portfolio. The company expects Ohtuvayre to drive strong long-term growth, extending its leadership in respiratory care.

Read full article here.